Therefore, elderly patients with anemia are likely to be deficient in iron and EPO, which are essential for the anemia-improving effects of SGLT2 inhibitors, and the treatment-induced increase in hemoglobin tends to be smaller than that in nonelderly patients. Here, SLC5A2 is linked to anemia.